It’s going to take me time to study these results, but they are certainly exciting. It looks like three new trials are being planned, all with great potential. I think this package ahould be very attractive for a BP with existing involvement in diabetes-CKD-CVD, and there are several. 

Regarding the low LDL group results, we need to know if most of the low GFR patients happened to be in that group. I’m trying to find that out.